<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432623</url>
  </required_header>
  <id_info>
    <org_study_id>PB04-001</org_study_id>
    <secondary_id>R33HL147845</secondary_id>
    <nct_id>NCT04432623</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of Benserazide in Thalassemia Intermedia</brief_title>
  <acronym>PB04-001</acronym>
  <official_title>A Phase 1b Sequential Open Label Dose Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenicia BioScience</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Phoenicia BioScience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by
      abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which
      delivers oxygen throughout the body.The diseases are characterized by hemolytic anemia, organ
      damage, and early mortality. Increases in another type of (normal) hemoglobin, fetal globin
      (HbF), which is normally silenced in infancy, reduces the severity of both conditions. Even
      incremental augmentation of fetal globin is established to reduce red blood cell pathology,
      anemia, certain complications, and to improve survival.

      This trial will evaluate an oral drug discovered in a high throughput screen, which increases
      fetal globin protein and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman
      primates and in transgenic mice. The study drug acts by suppressing 4 repressors of the fetal
      globin gene promoter in progenitor cells from thalassemia patients. The drug has been used
      for many years in a combination product for different actions - to enhance half-life and
      reduce side effects of an active drug- and is considered safe for chronic use.

      This trial will first evaluate 3 dose levels in small cohorts of nontransfused patients with
      beta thalassemia intermedia. The most active dose will then be evaluated in larger subject
      groups with beta thalassemia and other hemoglobinopathies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will first evaluate 3 doses of the investigational drug which are considered safe
      with chronic use in a combination therapeutic used widely for a neurologic disease in Europe
      and Canada. The doses to be studied are human equivalent doses of doses that are active in
      nonhuman primates in inducing high level fetal globin messenger ribonucleic acid (mRNA),
      protein, and proportions of red blood cells expressing fetal globin protein (F-cells).
      Additive effects are observed with hydroxyurea in sickle cell patients' cells in vitro.

      The study will first evaluate the study therapeutic in male and female patients who are 18
      years and older. After a screening period to obtain baseline medical and laboratory data, the
      study drug will be taken by mouth once per day, every other day. The first dose will be taken
      in a clinical unit, and thereafter will be taken at home for 12 weeks. Laboratory tests,
      physical exams, and tolerability will be assessed 6 times over 4 months, including for one
      month after completion of dosing.

      The cohorts will be enrolled sequentially. Each new cohort will begin after the prior lower
      dose cohort has received 2 weeks of treatment without serious adverse events related to the
      study drug. The dose that increases fetal globin assays to the highest degree will be
      evaluated in a larger group of subjects.Other regimens or test doses may be added as needed.
      The study drug is expected to be safe when added to most other medications.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 30, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Each higher dose level cohort will be enrolled after 2 weeks of treatment in the lower dose level. Additional doses or regimens may be added. Expansion cohorts at the most active dose will be evaluated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma drug concentration over time</measure>
    <time_frame>4 weeks</time_frame>
    <description>area under the curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>4 weeks</time_frame>
    <description>drug concentration (ng/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum plasma drug concentration (Cmin)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Minimum drug plasma concentration, (ng/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fetal hemoglobin (HbF)</measure>
    <time_frame>12 weeks</time_frame>
    <description>% and absolute (g/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>16 weeks</time_frame>
    <description>gram/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>F-cells</measure>
    <time_frame>12 weeks</time_frame>
    <description>% Red blood cells containing HbF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbF protein per cell</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean fluorescent intensity (MFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase (LDH)</measure>
    <time_frame>12 weeks</time_frame>
    <description>U/L</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Beta Thalassemia Intermedia</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A low dose, 1 mg/kg or 100 mg, by mouth, once per day, on Monday, Wednesday, and Friday for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 mg/kg, up to 200 mg/kg, by mouth once per day, on Monday, Wednesday, and Friday, for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg, up to 350 mg/kg, by mouth once per day, on Monday, Wednesday, and Friday, fpr 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The highest and well-tolerated dose, once per day on Monday, Wednesday, and Friday, for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benserazide Only Product</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>Expansion group</arm_group_label>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_label>Middle dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Beta thalassemia intermedia (BTI) or (NTDT, Non-Transfusion Dependent Thalassemia)
             with at least one documented beta thalassemia mutation, including HbE beta thalassemia

          -  18 to 45 years of age at time of consent

          -  Average of 2 total hemoglobin (Hgb) levels between 6.0 and 10.0 g/dL in the preceding
             6 months

          -  Able and willing to give consent and comply with all study procedures

          -  If female and of childbearing potential, must have a documented negative pregnancy
             test prior to entry and agree to use one or more locally medically accepted methods of
             contraception

        Exclusion Criteria:

          -  Red blood cell (RBC) transfusion within 2 months prior to administration of study
             medication

          -  Participating in a chronic transfusion program

          -  Pulmonary hypertension requiring oxygen therapy

          -  Use of erythropoiesis stimulating agents within 90 days of first dose

          -  Transaminases &gt; 3 times upper limit of institution normal (ULN)

          -  Total and direct bilirubin &gt; 3 times institution ULN

          -  Creatinine clearance &lt;75 mL/min/1.73 meter square (m2)

          -  Splenomegaly with spleen palpable &gt;4 cm below the left costal margin.

          -  Known infection with HIV or hepatitis C (untreated)

          -  Fever &gt; 38.5°C in the week prior to first administration of study medication

          -  Evidence of osteoporosis or osteomalacia

          -  Received other investigational systemic therapy within 30 days prior to first dose

          -  Narrow angle glaucoma

          -  Currently pregnant or breast feeding a child

          -  Known current drug or alcohol abuse

          -  Taking monoamine oxidase inhibitors

          -  Other co-morbidity that substantially increases subject risk for the study per
             Investigator discretion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Perrine, MD</last_name>
    <role>Study Director</role>
    <affiliation>Phoenicia BioScience</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Kuo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sylvia Singer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff Children's Hospital at Oakland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Perrine, MD</last_name>
    <phone>617 335-7002</phone>
    <email>sperrine@bu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Askin, RN</last_name>
    <phone>410 231-1512</phone>
    <email>Melissa.Askin@acroclinical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sylvia Singer, MD</last_name>
      <phone>510-428-3169</phone>
      <email>Sylvia.Singer@UCSF.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Ferguson, RN, NP</last_name>
      <phone>510- 428-3885</phone>
      <phone_ext>5324</phone_ext>
      <email>Jennifer.Ferguson@UCSF.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Phoenicia Bioscience</name>
      <address>
        <city>Weston</city>
        <state>Massachusetts</state>
        <zip>02493</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan Perrine, MD</last_name>
      <phone>617-335-7002</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Health Network and Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Kevin Kuo, MD</last_name>
      <phone>416 340-4800</phone>
      <phone_ext>6729</phone_ext>
      <email>kevin.kuo@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Anneliesse Justiniano, BS</last_name>
      <phone>416 340-4800</phone>
      <phone_ext>6729</phone_ext>
      <email>anneliesse.justiniano@uhn.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boosalis MS, Sangerman JI, White GL, Wolf RF, Shen L, Dai Y, White E, Makala LH, Li B, Pace BS, Nouraie M, Faller DV, Perrine SP. Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice. PLoS One. 2015 Dec 29;10(12):e0144660. doi: 10.1371/journal.pone.0144660. eCollection 2015.</citation>
    <PMID>26713848</PMID>
  </reference>
  <reference>
    <citation>Dai Y, Sangerman J, Luo HY, Fucharoen S, Chui DH, Faller DV, Perrine SP. Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cells Mol Dis. 2016 Jan;56(1):62-9. doi: 10.1016/j.bcmd.2015.10.004. Epub 2015 Oct 27.</citation>
    <PMID>26603726</PMID>
  </reference>
  <reference>
    <citation>Dai Y, Sangerman J, Nouraie M, Faller AD, Oneal P, Rock A, Owoyemi O, Niu X, Nekhai S, Maharaj D, Cui S, Taylor R, Steinberg M, Perrine S. Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer. Am J Hematol. 2017 Jan;92(1):E10-E11. doi: 10.1002/ajh.24590. Epub 2016 Nov 18.</citation>
    <PMID>27766663</PMID>
  </reference>
  <reference>
    <citation>Chen Z, Luo HY, Steinberg MH, Chui DH. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis. 2009 Mar-Apr;42(2):144-9. doi: 10.1016/j.bcmd.2008.12.003. Epub 2009 Jan 18.</citation>
    <PMID>19153051</PMID>
  </reference>
  <reference>
    <citation>Sedgewick AE, Timofeev N, Sebastiani P, So JCC, Ma ESK, Chan LC, Fucharoen G, Fucharoen S, Barbosa CG, Vardarajan BN, Farrer LA, Baldwin CT, Steinberg MH, Chui DHK. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. Blood Cells Mol Dis. 2008 Nov-Dec;41(3):255-258. doi: 10.1016/j.bcmd.2008.06.007. Epub 2008 Aug 8.</citation>
    <PMID>18691915</PMID>
  </reference>
  <reference>
    <citation>Zhou D, Liu K, Sun CW, Pawlik KM, Townes TM. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet. 2010 Sep;42(9):742-4. doi: 10.1038/ng.637. Epub 2010 Aug 1.</citation>
    <PMID>20676097</PMID>
  </reference>
  <reference>
    <citation>Cao H, Stamatoyannopoulos G, Jung M. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood. 2004 Jan 15;103(2):701-9. Epub 2003 Aug 14.</citation>
    <PMID>12920038</PMID>
  </reference>
  <reference>
    <citation>Franco RS, Yasin Z, Palascak MB, Ciraolo P, Joiner CH, Rucknagel DL. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood. 2006 Aug 1;108(3):1073-6.</citation>
    <PMID>16861353</PMID>
  </reference>
  <reference>
    <citation>Perrine RP, Brown MJ, Clegg JB, Weatherall DJ, May A. Benign sickle-cell anaemia. Lancet. 1972 Dec 2;2(7788):1163-7.</citation>
    <PMID>4117591</PMID>
  </reference>
  <reference>
    <citation>Wang X, Thein SL. Switching from fetal to adult hemoglobin. Nat Genet. 2018 Apr;50(4):478-480. doi: 10.1038/s41588-018-0094-z.</citation>
    <PMID>29610477</PMID>
  </reference>
  <reference>
    <citation>Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP; E/beta Thalassaemia Study Group. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br J Haematol. 2005 Nov;131(3):378-88.</citation>
    <PMID>16225658</PMID>
  </reference>
  <reference>
    <citation>Perrine SP, Mankidy R, Boosalis MS, Bieker JJ, Faller DV. Erythroid Kruppel-like factor (EKLF) is recruited to the gamma-globin gene promoter as a co-activator and is required for gamma-globin gene induction by short-chain fatty acid derivatives. Eur J Haematol. 2009 Jun;82(6):466-76. doi: 10.1111/j.1600-0609.2009.01234.x. Epub 2009 Feb 5.</citation>
    <PMID>19220418</PMID>
  </reference>
  <reference>
    <citation>Tanabe O, McPhee D, Kobayashi S, Shen Y, Brandt W, Jiang X, Campbell AD, Chen YT, Chang Cs, Yamamoto M, Tanimoto K, Engel JD. Embryonic and fetal beta-globin gene repression by the orphan nuclear receptors, TR2 and TR4. EMBO J. 2007 May 2;26(9):2295-306. Epub 2007 Apr 12.</citation>
    <PMID>17431400</PMID>
  </reference>
  <reference>
    <citation>Borg J, Papadopoulos P, Georgitsi M, Gutiérrez L, Grech G, Fanis P, Phylactides M, Verkerk AJ, van der Spek PJ, Scerri CA, Cassar W, Galdies R, van Ijcken W, Ozgür Z, Gillemans N, Hou J, Bugeja M, Grosveld FG, von Lindern M, Felice AE, Patrinos GP, Philipsen S. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet. 2010 Sep;42(9):801-5. doi: 10.1038/ng.630. Epub 2010 Aug 1.</citation>
    <PMID>20676099</PMID>
  </reference>
  <reference>
    <citation>Atweh GF, Sutton M, Nassif I, Boosalis V, Dover GJ, Wallenstein S, Wright E, McMahon L, Stamatoyannopoulos G, Faller DV, Perrine SP. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999 Mar 15;93(6):1790-7.</citation>
    <PMID>10068649</PMID>
  </reference>
  <reference>
    <citation>Centis F, Tabellini L, Lucarelli G, Buffi O, Tonucci P, Persini B, Annibali M, Emiliani R, Iliescu A, Rapa S, Rossi R, Ma L, Angelucci E, Schrier SL. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood. 2000 Nov 15;96(10):3624-9.</citation>
    <PMID>11071663</PMID>
  </reference>
  <reference>
    <citation>Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995 Jan 1;85(1):43-9.</citation>
    <PMID>7528572</PMID>
  </reference>
  <reference>
    <citation>Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971.</citation>
    <PMID>30021096</PMID>
  </reference>
  <reference>
    <citation>Minniti CP. l-Glutamine and the Dawn of Combination Therapy for Sickle Cell Disease. N Engl J Med. 2018 Jul 19;379(3):292-294. doi: 10.1056/NEJMe1800976.</citation>
    <PMID>30021091</PMID>
  </reference>
  <reference>
    <citation>Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007 Jan;21(1):37-47. Epub 2006 Nov 7. Review.</citation>
    <PMID>17084951</PMID>
  </reference>
  <reference>
    <citation>Saraf S, Farooqui M, Infusino G, Oza B, Sidhwani S, Gowhari M, Vara S, Gao W, Krauz L, Lavelle D, DeSimone J, Molokie R, Saunthararajah Y. Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease. Br J Haematol. 2011 May;153(3):386-92. doi: 10.1111/j.1365-2141.2010.08479.x. Epub 2011 Mar 21.</citation>
    <PMID>21418176</PMID>
  </reference>
  <reference>
    <citation>Perrine SP, Pace BS, Faller DV. Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies. Hematol Oncol Clin North Am. 2014 Apr;28(2):233-48. doi: 10.1016/j.hoc.2013.11.009. Review.</citation>
    <PMID>24589264</PMID>
  </reference>
  <reference>
    <citation>Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore). 2001 Sep;80(5):328-44. Review.</citation>
    <PMID>11552087</PMID>
  </reference>
  <reference>
    <citation>Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010 Jun 3;115(22):4331-6. doi: 10.1182/blood-2010-01-251348. Epub 2010 Mar 16. Review.</citation>
    <PMID>20233970</PMID>
  </reference>
  <reference>
    <citation>Taher AT, Cappellini MD. How I manage medical complications of β-thalassemia in adults. Blood. 2018 Oct 25;132(17):1781-1791. doi: 10.1182/blood-2018-06-818187. Epub 2018 Sep 11. Review.</citation>
    <PMID>30206117</PMID>
  </reference>
  <reference>
    <citation>Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007 Aug;138(3):291-304. Epub 2007 Jun 12. Review.</citation>
    <PMID>17565568</PMID>
  </reference>
  <reference>
    <citation>Sripichai O, Makarasara W, Munkongdee T, Kumkhaek C, Nuchprayoon I, Chuansumrit A, Chuncharunee S, Chantrakoon N, Boonmongkol P, Winichagoon P, Fucharoen S. A scoring system for the classification of beta-thalassemia/Hb E disease severity. Am J Hematol. 2008 Jun;83(6):482-4. doi: 10.1002/ajh.21130.</citation>
    <PMID>18186524</PMID>
  </reference>
  <reference>
    <citation>Nuinoon M, Makarasara W, Mushiroda T, Setianingsih I, Wahidiyat PA, Sripichai O, Kumasaka N, Takahashi A, Svasti S, Munkongdee T, Mahasirimongkol S, Peerapittayamongkol C, Viprakasit V, Kamatani N, Winichagoon P, Kubo M, Nakamura Y, Fucharoen S. A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E. Hum Genet. 2010 Mar;127(3):303-14. doi: 10.1007/s00439-009-0770-2.</citation>
    <PMID>20183929</PMID>
  </reference>
  <reference>
    <citation>Uda M, Galanello R, Sanna S, Lettre G, Sankaran VG, Chen W, Usala G, Busonero F, Maschio A, Albai G, Piras MG, Sestu N, Lai S, Dei M, Mulas A, Crisponi L, Naitza S, Asunis I, Deiana M, Nagaraja R, Perseu L, Satta S, Cipollina MD, Sollaino C, Moi P, Hirschhorn JN, Orkin SH, Abecasis GR, Schlessinger D, Cao A. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1620-5. doi: 10.1073/pnas.0711566105. Epub 2008 Feb 1.</citation>
    <PMID>18245381</PMID>
  </reference>
  <reference>
    <citation>Labie D, Pagnier J, Lapoumeroulie C, Rouabhi F, Dunda-Belkhodja O, Chardin P, Beldjord C, Wajcman H, Fabry ME, Nagel RL. Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci U S A. 1985 Apr;82(7):2111-4.</citation>
    <PMID>2580306</PMID>
  </reference>
  <reference>
    <citation>Silva M, Grillot D, Benito A, Richard C, Nuñez G, Fernández-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996 Sep 1;88(5):1576-82.</citation>
    <PMID>8781412</PMID>
  </reference>
  <reference>
    <citation>Pootrakul P, Sirankapracha P, Hemsorach S, Moungsub W, Kumbunlue R, Piangitjagum A, Wasi P, Ma L, Schrier SL. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. Blood. 2000 Oct 1;96(7):2606-12.</citation>
    <PMID>11001918</PMID>
  </reference>
  <reference>
    <citation>Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E. Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. Br J Haematol. 2011 Jul;154(2):281-4. doi: 10.1111/j.1365-2141.2011.08617.x. Epub 2011 Apr 18.</citation>
    <PMID>21496003</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-transfusion dependent beta thalassemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benserazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Results will be provided in abstracts as the study is being conducted and in a publication after completion and analysis.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

